Sign In
Buy NORD
$3.90
-0.110 (-2.74%)
At Close: Jun 05, 2026
Nordicus Partners Corporation Corporate Update
11:55am, Friday, 06'th Feb 2026
BEVERLY HILLS, California, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supportin
Nordique Announces Change in CEO and Director
08:00am, Thursday, 29'th Jan 2026
Vancouver, British Columbia – TheNewswire - January 29, 2026 – Nordique Resources Inc. (CSE: NORD) (the “Company” or “Nordique ”) is pleased to announce that James Hocking has been appoint
NoviThera has initiated the first efficacy animal studies
11:00am, Thursday, 13'th Nov 2025
BEVERLY HILLS, California, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NoviThera ApS (“NoviThera”), a majority owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Compa
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.
09:00am, Wednesday, 22'nd Oct 2025
BEVERLY HILLS, California, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financi
Orocidin develops novel cGMP manufacturing process in collaboration with Syngene
09:00am, Monday, 20'th Oct 2025
The partnership addressed complex peptide synthesis and purification challenges to achieve high yield and purity suitable for clinical use BEVERLY HILLS, California, Oct. 20, 2025 (GLOBE NEWSWIRE) --
Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS
04:38pm, Friday, 03'rd Oct 2025
BEVERLY HILLS, California, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supportin
Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market
09:53am, Tuesday, 02'nd Sep 2025
BEVERLY HILLS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic an
Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors
09:50am, Thursday, 07'th Aug 2025
Beverly Hills, California, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a business accelerator and holding company specializing
Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia
10:45am, Thursday, 03'rd Apr 2025
BEVERLY HILLS, California, April 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs
11:27am, Wednesday, 02'nd Apr 2025
BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financ
Orocidin and Syngene Partner to Accelerate Biotech Innovation
11:00am, Thursday, 20'th Feb 2025
BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financi
Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study
11:48am, Tuesday, 18'th Feb 2025
BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financi
Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia
11:03am, Monday, 03'rd Feb 2025
BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a f
Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment
11:25am, Tuesday, 28'th Jan 2025
BEVERLY HILLS, California, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting com
Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin's Breakthrough Treatment for Periodontitis
02:00pm, Tuesday, 14'th Jan 2025
BEVERLY HILLS, California, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supportin
